edgepedia

Life and health

72,234 articles

Leukotriene A4 hydrolase/leucine aminopeptidase

Leukotriene A4 hydrolase (LTA4H, EC 3.3.2.6) is a human 611-amino-acid bifunctional zinc metalloenzyme: its epoxide hydrolase activity makes pro-inflammatory LTB4, while its aminopeptidase activity degrades the chemoattractant peptide Pro-Gly-Pro.

Leukotriene B4

Leukotriene B4 (LTB4) is an inflammatory lipid mediator made from arachidonic acid by the 5-lipoxygenase pathway and one of the most potent chemoattractants for leukocytes.

Leukotriene B4 receptor

Leukotriene B4 receptor: the GPCRs BLT1 and BLT2 that bind leukotriene B4, an arachidonate-derived chemoattractant. BLT1 is high-affinity and pro-inflammatory; BLT2 is low-affinity, activated by 12-HHT, and protective.

Leukotriene C4

Leukotriene C4 is a cysteinyl leukotriene, formed by conjugating leukotriene A4 with glutathione and first identified as the slow-reacting substance of anaphylaxis; it constricts airways and drives asthma.

Leukotriene E4

Leukotriene E4 is the final and most stable cysteinyl leukotriene, formed from arachidonic acid, that drives bronchoconstriction and whose urinary measurement marks whole-body cysteinyl leukotriene production.

Leukotriene receptors

Leukotriene receptors are G protein-coupled receptors for leukotriene lipid mediators: BLT1 and BLT2 bind LTB4, CysLT1 and CysLT2 bind cysteinyl leukotrienes; CysLT1 antagonists treat asthma.

Leupeptin

Leupeptin (Ac-Leu-Leu-Arg-H, Gabadur) is a cell-permeable tripeptide aldehyde protease inhibitor discovered in 1969 from Streptomyces; it reversibly inhibits serine, cysteine, and threonine peptidases and is used in protein extraction and autophagy assays.

Leuprorelin

Leuprorelin is a synthetic GnRH analog that suppresses sex hormones. Approved by the FDA in 1985, it is used to treat prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

Levacetylleucine

Levacetylleucine, also known as N-acetyl-L-leucine and marketed as Aqneursa, is an oral drug approved in 2024 for neurological symptoms of Niemann-Pick disease type C and in 2026 for ataxia in ataxia-telangiectasia.

Levallorphan

Levallorphan (Lorfan) is a discontinued morphinan opioid antagonist with partial kappa-agonist activity, used to reverse opioid respiratory depression; unlike naloxone it depresses respiration and was superseded by it.

Levamfetamine

Levamfetamine (levoamphetamine, L-amphetamine) is the (R)-enantiomer of amphetamine, C9H13N, CAS 156-34-3. Weaker CNS stimulant than dextroamphetamine but stronger peripherally; US anorectic products withdrawn in 1973; distinct from levmetamfetamine.

Levamisole

Levamisole, also called tetramisole's laevo isomer (brand Ergamisol, Decaris), is a synthetic imidazothiazole anthelmintic and immunomodulator acting at nematode L-subtype nicotinic acetylcholine receptors; withdrawn for human use in the US (2000) and EU (2026), still used in veterinary medicine.

Levamlodipine

Levamlodipine, also called (S)-amlodipine or levoamlodipine (brand Conjupri), is the active S-enantiomer of the racemic calcium channel blocker amlodipine, FDA-approved December 19, 2019 for hypertension; 5 mg is bioequivalent to 10 mg racemic amlodipine.

Levator ani

Levator ani, the main pelvic diaphragm muscle made of puborectalis, pubococcygeus, and iliococcygeus; supports pelvic viscera, maintains continence, innervated mainly by S3-S4, injured in 13-36% of vaginal deliveries.

Levator scapulae muscle

Levator scapulae (musculus levator scapulae), a neck and upper back muscle from cervical transverse processes C1-C4 to the scapula's medial border; elevates the scapula, innervated by C3, C4, and the dorsal scapular nerve (C5), and notably variable with accessory slips.

Level of support for evolution

Level of support for evolution: public acceptance of evolutionary theory, measured by Pew and Gallup surveys. US acceptance rose from 40% to 54% (1985–2020); 98% of American scientists accept it; acceptance varies widely by country and question wording.

Levetiracetam

Levetiracetam (Keppra) is an SV2A-binding antiseizure medication approved by the FDA in 1999 and in the EU in 2000, used as first-line monotherapy or add-on for focal and generalized seizures, with somnolence and headache as common side effects.

Levi A. Garraway

Levi A. Garraway is an American oncologist and cancer genomicist who is Chief Medical Officer at Roche, co-founded Foundation Medicine, and pioneered high-throughput tumor genome profiling.

Levilactobacillus brevis

Levilactobacillus brevis, formerly Lactobacillus brevis, is a gram-positive, heterofermentative lactic acid bacterium used in silage, sourdough, beer, and wine fermentation, known for GABA production, QPS status since 2007, and probiotic strains.

Levilimab

Levilimab (BCD-089, Ilsira) is a fully human IgG1 monoclonal antibody against the interleukin-6 receptor from Biocad, Russia; approved there in 2020 for severe COVID-19 cytokine release syndrome and studied in rheumatoid arthritis; ATC L04AC25; no US/EU approval.

Leviviricetes

Leviviricetes, formerly Allassoviricetes, is a class of single-stranded RNA viruses that infect bacteria, expanded by the ICTV in 2021 to include the phage MS2, whose genome was the first ever sequenced.

Levo-Transposition of the great arteries

Levo-transposition of the great arteries (L-TGA, ccTGA) is a rare congenital heart defect with double discordance leaving the right ventricle systemic; over 80% have associated lesions, and heart block, tricuspid regurgitation, and ventricular failure dominate management.

Levobetaxolol

Levobetaxolol is the active S-isomer of the beta blocker betaxolol, given as eye drops to lower intraocular pressure in open-angle glaucoma and ocular hypertension; it debuted in the early 1980s.

Levobunolol

Levobunolol (levobunolol hydrochloride ophthalmic solution) is a noncardioselective topical beta-blocker, distinct from timolol and betaxolol, used once or twice daily to lower intraocular pressure in open-angle glaucoma and ocular hypertension.

Levocabastine

Levocabastine, a potent selective second-generation H1 antihistamine (C26H29FN2O2), is a topical eye-drop and nasal-spray treatment for allergic conjunctivitis and rhinitis, first approved around 1990 and now discontinued in many markets.

Levocetirizine

Levocetirizine (Xyzal) is the R-enantiomer of cetirizine, an oral second-generation H1 antihistamine for allergic rhinitis and chronic idiopathic urticaria; 5 mg once daily, renally cleared, FDA 2025 warning on severe post-discontinuation itching.

Levodopa

Levodopa (L-DOPA) is a naturally occurring amino acid and direct precursor of dopamine, converted to dopamine in the brain; it has been the gold-standard therapy for Parkinson's motor symptoms since 1967, usually given with carbidopa.

Levodropropizine

Levodropropizine, the levo (S)-enantiomer of dropropizine, is a non-opioid peripheral antitussive acting on airway C-fibers; used for dry cough in Europe (not US-approved), dosed 60 mg three times daily.

Levofloxacin

Levofloxacin (Cravit, Tavanic, Levaquin) is a third-generation fluoroquinolone antibiotic, the S-(-) isomer of ofloxacin, inhibiting DNA gyrase and topoisomerase IV; FDA-approved 1996 for pneumonia, UTIs, skin infections, anthrax, and plague, with a boxed warning for tendon and nerve injury.

Levoketoconazole

Levoketoconazole (Recorlev) is the 2S,4R enantiomer of ketoconazole, an oral cortisol synthesis inhibitor approved by FDA on December 30, 2021 for endogenous hypercortisolemia in adults with Cushing's syndrome, with boxed warnings for hepatotoxicity and QT prolongation.